Clinical and pharmacological group: & nbsp

Anticoagulants

Included in the formulation
  • Glyugitsir
    solution
    BIOSINTEZ, PAO     Russia
  • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    V.07.A.C   Aids for blood transfusion

    Pharmacodynamics:

    Anticoagulant. Binds Ca2+ (IV plasma factor of blood coagulability) and prevents hemocoagulation in vitro. Contained in the preparation dextrose serves as an energy substratum (serves as a food for blood cells); participates in the metabolism, enhances oxidation-reduction processes, improves the antitoxic function of the liver.

    Pharmacokinetics:

    Dextrose

    Absorption is fast. The maximum concentration is indicated 40 minutes after ingestion. Biotransformation occurs in the liver: through the formation of pyruvate or lactic acid is metabolized to water and carbon dioxide with the release of energy. Completely metabolized, not eliminated (presence in the urine - pathology).

    Sodium citrate

    After absorption, it is metabolized to bicarbonate, excreted by urine and increasing its volume and hydrogen index.

    Indications:

    Preservation of blood.

    XXI.Z40-Z54.Z51.3   Blood transfusion without a specified diagnosis

    XXI.Z40-Z54.Z51.4   Preparatory procedures for subsequent treatment,not elsewhere classified

    Contraindications:

    Increased bleeding, hypersensitivity.

    Carefully:

    No data.

    Pregnancy and lactation:

    Category Food and Drug Administration (US Food and Drug Administration) not determined. Adequate and well-controlled studies in humans and animals have not been conducted. There is no information on the penetration into breast milk.

    Dosing and Administration:

    In accordance with the "Instruction on the harvesting of preserved blood."

    Side effects:

    Cramps, nausea, arrhythmia, chills, pollakiuria, allergic reactions, with a rapid infusion (infusion rate of more than 5 ml per minute) of a large number of blood components harvested using hemoconvant, there is a risk of citrated nephrotoxicity, hepatotoxicity, hypokalemia, with rapid massive transfusion of cold blood components - hypothermia with risk of arrhythmia, hypoxia.

    Overdose:

    Hepatotoxicity, nephrotoxicity citrate. Treatment is symptomatic.

    Interaction:

    You can not mix the blood components harvested using formulation with other agents.

    Special instructions:

    Dextrose, which is contained in the drug, serves as a nutrient substrate. Shelf life of preserved blood at a temperature of 2-6 ° C is 21 days. Before use, check the integrity of the consumer container and the tightness of the container.

    Instructions
    Up